Member Info for Muminr

For those interested, here is a article by Peter Doshi, an editor at the BMJ. It relates to the Pfizer and Moderna vaccines, but the issues apply to AZ also.

In summary, the vaccine results may be overstated and a re-analysis may put the effectiveness as low as 19-29%, due to 3410 suspected Covid-19 cases in the trials not being further investigated. There were numerous other shortcomings in the trials which makes for a very interesting read.

How it relates to GDR, is that I think whilst general opinion in currently focused on vaccination and not testing, and this approach may be exonerated over spring and summer, come winter 2021 we may have a resurgence with focus shifting back to testing.

https://blogs.bmj.com/bmj/2021/01/04/peter-doshi-pfizer-and-modernas-95-effective-vaccines-we-need-more-details-and-the-raw-data/

Many thanks Jay! That fills me with even more optimism. RNS may not be tomorrow, but it will come in due course!

Study published in the Lancet on 4th February 2021, funded by the US National Institutes of Health, US Centers for Disease Control and Prevention concludes "Extensive expansion of SARS-CoV-2 testing programmes with more frequent and rapid tests across communities" needed.

https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(21)00002-5/fulltext

An announcement may come next week, or the week after...we just need to be patient...

Many thanks ST, excellent find!

Technick, many thanks for the interesting insights into virus mutations.

I have a background in conducting clinical trials and whilst I appreciate that nobody wants to be a killjoy, I am flabbergasted at widespread unquestioning acceptance of the vaccine efficacy claims. The key issue in a trial, for statistical predictive power, is not how many subjects you had at the start but rather how many end-points you have to compare between the 2 groups. In the vaccine trials this appears to be between 90 and 130. If you stratify this for different age categories or co-morbidities you're left with less than a dozen in each strata. This is not good enough for robust conclusions. In my view, things will start to unravel once we have data on 100,000s of people, may be in about 6 months.

The other elephant in the room that none of the studies have addressed, is how long any immunity lasts. There have been published studies, albeit limited, that suggest individuals being reinfected after a matter of weeks. Anything less than 1 year would be disappointing for a vaccine. In any case, to determine the length of immunity in a meaningful population you would need continuous mass testing globally for a long time.

I am sure LTH holders of GDR will be rewarded for their patience.

Many thanks for that starrenstoff. It should to be interesting.

Hi folks, does anyone know when is the presentation tomorrow and how to access it?

Good interview. The comparison with other Covid tests was excellent - our product is "unique and the best in the world". Just have to be patient for sales.